Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.

ABSTRACT:

Background & aims

The aim of the study was to evaluate the efficacy and safety of adjuvant sorafenib treatment compared with placebo in patients with hepatocellular carcinoma who underwent local ablation.

Methods

The SORAMIC trial is a randomised controlled trial with diagnostic, local ablation, and palliative sub-study arms. After initial imaging within the diagnostic study, patients were assigned to local ablation or palliative arms. In the local ablation cohort, patients were randomised 1:1 to local ablation + sorafenib vs. local ablation + placebo. The primary endpoint was time-to-recurrence (TTR). Secondary endpoints were local control rate and safety in terms of adverse events and quality-of-life.

Results

The recruitment was terminated prematurely after 1

SUBMITTER: Seidensticker M 

PROVIDER: S-EPMC10031000 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature